Safety, Tolerability and PK of Multiple-ascending Doses of Emodepside

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-11-14

Study Completion Date

2018-10-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study evaluates safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of emodepside, after administration as a Liquid Service Formulation (LSF), over 10 days, in healthy male caucasian subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Emodepside Phase II Trial for Treatment of Onchocerciasis

NCT05180461

Onchocerciasis

ACTIVE_NOT_RECRUITING PHASE2

Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

NCT06800248

Trichuris Trichiura; Infection Hookworm Infection Ascaris Lumbricoides Infection

NOT_YET_RECRUITING PHASE3

A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants

NCT06412926

Soil-transmitted Helminth Infection Onchocerciasis (River Blindness)

COMPLETED PHASE1

Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV371 LAI in Healthy Participants

NCT06558643

Malaria,Falciparum

COMPLETED PHASE1

A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis

NCT05593666

Primary Visceral Leishmaniasis

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O. volvulus adult worms, which could be used in individual case management and, after appropriate testing, as an alternative drug to ivermectin in Mass Drug Administration (MDA) programs. Emodepside is a promising candidate to kill the adult and sexually mature O. volvulus as explained below. Emodepside was shown to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for animal health, commercialized by Bayer AG under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril).

A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of emodepside in healthy Caucasian men has been conducted and the preliminary results are favourable, supporting continuation of the Phase I development program. In the present repeat dose study, PK as well as safety and tolerability of the liquid service formulation of emodepside, given over 10 days, will be tested.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Filariasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cohort 1 (8 subjects)

6 subjects with LSF emodepside 5mg, OD 2 subjects with matching placebo

Group Type EXPERIMENTAL

LSF emodepside (BAY 44-4400) or matching placebo

Intervention Type DRUG

Emodepside administered as an LSF oral solution (1mg/mL)

cohort 2 (8 subjects)

6 subjects with LSF emodepside 10mg, OD 2 subjects with matching placebo

Group Type EXPERIMENTAL

LSF emodepside (BAY 44-4400) or matching placebo

Intervention Type DRUG

Emodepside administered as an LSF oral solution (1mg/mL)

cohort 3 (8 subjects)

6 subjects with LSF emodepside 10mg, BID 2 subjects with matching placebo

Group Type EXPERIMENTAL

LSF emodepside (BAY 44-4400) or matching placebo

Intervention Type DRUG

Emodepside administered as an LSF oral solution (1mg/mL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LSF emodepside (BAY 44-4400) or matching placebo

Emodepside administered as an LSF oral solution (1mg/mL)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male, Caucasian volunteers, deemed healthy based on a clinical history, physical examination, ECG, vital signs, and laboratory tests of blood and urine.
2. 18 to 45 years of age.
3. Normal body weight (BMI; Quetelet index) in the range 18 to 30.1 kg/m2 at screening.
4. Blood pressure and heart rate in the supine position prior to randomisation must be within the ranges 90-140 mm Hg systolic, 60-90 mm Hg diastolic; heart rate 45-100 beats/min.
5. Sufficient intelligence to understand the nature of the trial and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
6. Willingness to give written consent to participate, after reading the information and consent form, and after having the opportunity to discuss the trial with the Investigator or his delegate.
7. Willingness to give written consent to have data entered into the Overvolunteering Prevention System.
8. Willingness to agree to the contraceptive requirements of the study from the first dose until 120 days after the last dose of study medication.

Exclusion Criteria

1. Administration of a licensed or unlicensed medicinal product as part of another clinical trial within the 3 months before, or within 5 half-lives of, their first dose of study medication, whichever is longer, or is currently in the follow-up period for any clinical trial.
2. Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness (such as diabetes mellitus or other abnormalities of glucose homeostasis) sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
3. Past surgery (e.g., stomach bypass) or medical condition that might affect absorption of study drug taken orally.
4. Presence of abnormal physical findings, ECG, or laboratory values at the pre-trial screening assessment that could interfere with the objectives of the trial or the safety of the subject.
5. Loss of more than 400 mL of blood within 3 months before admission.
6. Clinically relevant history of vital organ disease or other disease of an organ or the central nervous system.
7. Current or previous medical or psychiatric disorder, condition or history of such (e.g., seizures) that, in the opinion of the Investigator or the Sponsor, would increase the risk associated with study participation, or impair the subject's ability to participate or complete this study.
8. Positive test for hepatitis B, hepatitis C or HIV.
9. Febrile illness within 1 week before the first dose of study medication.
10. History of severe allergy, non-allergic drug reactions, severe adverse reaction to any drug, or multiple drug allergies.
11. Subjects with hypersensitivity to any ingredient of the study medication, including the active ingredient, emodepside.
12. Presence or history of drug or alcohol abuse in the last 10 years, or intake of more than 21 units of alcohol weekly.
13. Regular daily consumption of more than one liter of xanthine-containing beverages.
14. Regular daily consumption of more than 5 cigarettes daily, or use more than 3 grams (1/8 ounce) of tobacco.
15. Use of a prescription medicine during the 28 days before the first dose of study medication or use of an over-the-counter medicine (with exception of acetaminophen \[paracetamol\]), during the 7 days before the first dose of study medication.
16. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be inducers or inhibitors of CYP3A4, or other co-medications known to be relevant substrates of CYP3A4, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
17. Use of dietary supplements or herbal remedies (such as St John's Wort) that are known to be strong inhibitors of P-gp, or other co-medications known to be relevant substrates of P-gp, during the 28 days before the first dose of study medication (see list in the Study Procedures Manual).
18. Relevant pathological abnormalities in the ECG at screening, such as a second or third-degree atrioventricular (AV) block or prolongation of the QRS complex over 120 msec or QTc-interval over 450 msec (corrected using Bazett's \[QTcB\] or Fridericia's \[QTcF\] formulae).
19. Evidence of drug abuse (via urine testing) at the screening assessment or admission to the ward.
20. Use of excluded therapies that may impact on the interpretation of study results in the opinion of the Investigator or Sponsor.
21. Objection by General Practitioner (GP) to subject entering trial.
22. History of residing for 6 or more continuous months, within the last 3 years, in regions with endemic parasitic infections as determined by the Investigator.
23. Possibility that subject will not cooperate with the requirements of the protocol.
24. No contact lenses wear within 1 month before dosing. Wearing contact lenses is not permitted during the study.
25. Any ocular disorder for which topical ocular therapy is currently or chronically prescribed, including inflammatory eye disease (dry eye allergic conjunctivitis \[seasonal allergic conjunctivitis, vernal keratoconjunctivitis, atopic keratoconjunctivitis\], uveitis and glaucoma).
26. Past history of ocular disease requiring ongoing treatment.
27. Past ocular surgery including laser or other refractive corneal surgery.
28. Evidence of eye irritation, visual difficulties, corneal opacity, ocular surface (corneal or conjunctival damage, with or without ocular symptoms).
29. Evidence of narrow anterior chamber angles causing increased risk of acute glaucoma.
30. Evidence of ocular media opacity including lens opacity/vitreous opacities.
31. Evidence of retinal or optic nerve pathology.
32. Evidence of pronounced colour blindness, as indicated by an Ishihara score of 9/13 or below.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes